




an Open Access Journal by MDPI

Pharmacoepidemiology

A red-tinted background image showing laboratory glassware, including test tubes and beakers, with a focus on the liquid inside them.

[mdpi.com/
journal/
pharmacoepidemiology](https://mdpi.com/journal/pharmacoepidemiology)



Message from the Editor-in-Chief

We are very proud to launch this new, international, peer-reviewed, and open access journal. The main aim of *Pharmacoepidemiology* is to publish novel and up-to-date research findings, reviews, and communications on the beneficial effects of drugs as well as their potential adverse effects on humans through epidemiological studies conducted in the real world on large populations.

All researchers working in the pharmacoepidemiologic field—such as epidemiologists, clinical researchers, pharmacologists, clinicians, and biostatisticians—are welcome to contribute to *Pharmacoepidemiology*.

Editor-in-Chief

Dr. Carlotta Franchi

Aims

Pharmacoepidemiology (ISSN 2813-0618) is an international, peer-reviewed, open access journal that publishes original articles, critical reviews, and short communications on high-quality studies across the fields of pharmacoepidemiology, clinical pharmacology, and epidemiology. The aim of *Pharmacoepidemiology* is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. Therefore, the journal has no restriction on the maximum length of the papers. Full experimental details should be provided so that the results can be reproduced.

Scope

- Designs, analyses, results, and interpretations of studies on drugs, biologics, or medical devices;
- Molecular pharmacoepidemiology;
- Methodology of pharmacoepidemiology;
- Pharmacovigilance;
- Patient safety;
- Patterns of drug utilization;
- Post-marketing surveillance;
- Pharmacoeconomics;
- Formulation and interpretation of regulatory guidelines;
- Studies on the benefits/safety/effectiveness of pharmaceuticals, biologics, or medical devices;
- Harm/benefit assessments in drug therapy;
- Evaluation of risk management plans on pharmaceuticals, biologics, and medical devices.

Author Benefits

Open Access

Unlimited and free access for readers

No Copyright Constraints

Retain copyright of your work and free use of your article

Thorough Peer-Review

Discounts on Article Processing Charges (APC)

If you belong to an institute that participates with the MDPI Institutional Open Access Program

No Space Constraints, No Extra Space or Color Charges

No restriction on the maximum length of the papers, number of figures or colors

Rapid Publication

A first decision is provided to authors approximately 29.5 days after submission; acceptance to publication is undertaken in 4.7 days (median values for papers published in this journal in the second half of 2024)

MDPI is a member of


CASPA



STM¹

| C | O | P | E |

SPARC*
Europe



DOAJ



ORCID



Editorial Office

pharmacoepidemiology@mdpi.com

MDPI

Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

mdpi.com

January 2025

